HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study

AIDS

Volumn 15, Issue 14, 2001, Pages 1811-1822

  Carr, Andrew ^a   Hudson, Jeff ^b   Chuah, John ^c   Mallal, Simon ^d   Law, Matthew ^e   Hoy, Jennifer ^e   Doong, Nicholas ^f   French, Martyn ^d   Smith, Don ^e   Cooper, David A ^f  

^a ST VINCENT S HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c Gold Coast Sexual Health Clinic   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f NONE

Author keywords

HIV; Hyperlipidaemia; Insulin resistance; Lipodystrophy; Protease inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYUREA; NEVIRAPINE; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CARNITINE; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROXYUREA; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; MIDDLE AGED; NEVIRAPINE; PHOSPHONIC ACIDS; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0035964696     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109280-00010     Document Type: Article

References (33)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Visceral abdominal-fat accumulation associated with use of indinavir
3. 'Buffalo hump' in men with HIV-1 infection
4. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus
5. Description of lipodystrophy in HIV Outpatients Study (HOPS)
6. The Australian prevalence survey of lipodystrophy syndrome
7. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study
8. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients
9. Insulin resistance in HIV protease inhibitor-associated diabetes
10. Inhibition of adipocyte differentiation by HIV protease inhibitors
11. 1 acid signaling by the HIV protease inhibitor indinavir
12. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
13. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
14. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
15. Contribution of nucleosides analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
16. Effects of nucleoside reverse transcriptase inhibitors on adipogenesis and adipocyte metabolism
17. Severe premature coronary artery disease with protease inhibitors
18. Vascular complications associated with HIV protease inhibitors
19. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
20. ACTG364 - Nelfinavir and/or efavirenz in combination with new NRTIs in nucleoside experienced subjects: Week 48 ultrasensitive HIV RNA results
21. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
22. Report of the expert committee on the diagnosis and classification of diabetes mellitus
23. Variations in population health status: Results from a United Kingdom national questionnaire survey
24. Analysis of HIV-1 clinical trials: Statistical magic?
25. Subgroup analysis and other (mis)uses of baseline data in clinical trials
26. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized, controlled trial
27. Adverse effects of antiretroviral therapy
28. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
29. Improvement of lipodystrophy in HIV-1-infected subjects switching from 2 NRTI/PI to 2 NRTI/abacavir
30. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized, controlled trial
31. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
32. Transgenic mice lacking white fat: Models for understanding human lipoatrophic diabetes
33. Generalized lipodystrophy, congenital and acquired